Analysis of gene dosage on chromosome 11 in children suffering from Beckwith-Wiedemann syndrome.
The Beckwith-Wiedemann syndrome (BWS) is composed of multiple congenital malformations coupled with a high concurrent risk for the development of specific rare childhood tumours. The syndrome is characterised by a complex mode of inheritance, but recent evidence indicates that it is an autosomal dominant trait with variable penetrance. It has been previously suggested that major rearrangements of the short arm of chromosome 11 are involved in the aetiology of the disease. We undertook to search for rearrangements in 11p in four patients with BWS and their parents and siblings. By using cloned DNA fragments homologous to four genes located on 11p, namely catalase, parathyroid hormone, insulin-like growth factor II and the proto-oncogene c-Ha-Ras, we subjected DNA from the patients to a restriction fragment length polymorphism (RFLP) analysis after digestion with restriction enzymes. We found no evidence for any large scale deletions or amplifications in this chromosomal region. We therefore conclude that altered gene dosage is not, as has been suggested, a requirement for the development of BWS. This raises the question of whether some other molecular mechanism is responsible for the malformations observed.
Schofield
P N
PN
Department of Zoology, University of Oxford, United Kingdom.
Lindham
S
S
Engström
W
W
D000293:Adolescent; D001506:Beckwith-Wiedemann Syndrome / Q000235:genetics*; D002648:Child; D002872:Chromosome Deletion; D002874:Chromosome Mapping; D002880:Chromosomes, Human, Pair 11; D004247:DNA / Q000235:genetics; D015342:DNA Probes; D005260:Female; D005784:Gene Amplification; D015321:Gene Rearrangement; D006801:Humans; D008297:Male; D012150:Polymorphism, Restriction Fragment Length; D000090063:Proto-Oncogene Mas
D015342:DNA Probes; C000715470:MAS1 protein, human; D000090063:Proto-Oncogene Mas; D004247:DNA